Gefikin 250 mg (Tablet)
Unit Price: ৳ 250.00 (4 x 7: ৳ 7,000.00)
Strip Price: ৳ 1,750.00
Medicine Details
Category | Details |
---|---|
Generic | Gefitinib |
Company | Ziska pharmaceuticals ltd |
Indications
- First-line treatment for metastatic non-small cell lung cancer
- Patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
- Detectable by FDA-approved test
Pharmacology
- Reversibly inhibits kinase activity of wild-type and certain activating mutations of EGFR
- Prevents autophosphorylation of tyrosine residues
- Blocks EGFR-dependent proliferation
- Inhibits IGF and PDGF-mediated signalling
- Higher binding affinity for EGFR mutations than wild-type EGFR
Dosage & Administration
- Recommended dose: 250 mg orally once daily
- Can be taken with or without food
- Do not take a missed dose within 12 hours of the next dose
- For patients with difficulty swallowing solids: tablets can be immersed in water and administered
Interaction
- CYP3A4 inducers increase metabolism and decrease plasma concentrations
- CYP3A4 inhibitors decrease metabolism and increase plasma concentrations
Contraindications
- Known hypersensitivity to Gefitinib or any other components of the drug
Side Effects
- Interstitial Lung Disease
- Hepatotoxicity
- Gastrointestinal Perforation
- Severe or Persistent Diarrhea
- Ocular Disorders including Keratitis
- Bullous and Exfoliative Skin Disorders
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Potential hazard to the fetus or risk for loss of the pregnancy
- Unknown excretion in human milk
- Discontinue breastfeeding during treatment
Precautions & Warnings
- ILD-like adverse drug reactions occurred in 1.3% of patients
- Prompt investigation for ILD in case of worsened respiratory symptoms
- Periodic liver function testing required
- Discontinue in case of severe hepatic impairment or gastrointestinal perforation
- Withhold for severe or persistent diarrhea or ocular disorders
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- Monitor adverse reactions in patients with renal or hepatic impairment
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store between 20-25°C
- Store in a cool and dry place away from sunlight
- Keep out of the reach of children